Human hypoxia models in aerospace medicine: Potential applications for human pharmacological research.
aerospace medicine
drug development
human models
hypoxia
review
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
31 Mar 2024
31 Mar 2024
Historique:
revised:
07
02
2024
received:
21
06
2023
accepted:
17
02
2024
medline:
1
4
2024
pubmed:
1
4
2024
entrez:
31
3
2024
Statut:
aheadofprint
Résumé
Aerospace medicine required controlled terrestrial models to investigate influences of altered atmosphere conditions, such as hypoxia, on human health and performance. These models could potentially be expanded to encompass disease conditions or treatment targets regulated through hypoxia or hypercapnia. Hypoxia, a condition in which the body is deprived of adequate oxygen supply, profoundly affects human physiology at multiple levels and contributes to the pathogenesis of various diseases. Experimental exposure to hypoxic conditions has gained recognition as a model for studying diseases such as pulmonary hypertension, chronic obstructive pulmonary disease, obstructive sleep apnoea, migraine and kidney disease. This approach may be particularly useful in mechanism-oriented early-stage clinical studies. This review discusses the ability of hypoxia models from space medicine research to mimic or induce these conditions in a controlled laboratory setting as a tool for testing the efficacy and safety of new pharmaceutical interventions.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Norcross JR, Conkin J, Wessel JH III, et al. Evidence report: risk of hypobaric hypoxia from the exploration atmosphere; 2015.
Law J, Van Baalen M, Foy M, et al. Relationship between carbon dioxide levels and reported headaches on the International Space Station. J Occup Environ Med. 2014;56(5):477‐483. doi:10.1097/JOM.0000000000000158
Cottrell JJ. Altitude exposures during aircraft flight. Flying higher. Chest. 1988;93(1):81‐84. doi:10.1378/chest.93.1.81
Basner M, Stahn AC, Nasrini J, et al. Effects of head‐down tilt bed rest plus elevated CO(2) on cognitive performance. J Appl Physiol (1985). 2021;130(4):1235‐1246. doi:10.1152/japplphysiol.00865.2020
Hall DA, Hanrott K, Badorrek P, et al. Effects of recombinant human angiotensin‐converting enzyme 2 on response to acute hypoxia and exercise: a randomised, placebo‐controlled study. Pulm Ther. 2021;7(2):487‐501. doi:10.1007/s41030‐021‐00164‐7
Ruthenborg RJ, Ban JJ, Wazir A, Takeda N, Kim JW. Regulation of wound healing and fibrosis by hypoxia and hypoxia‐inducible factor‐1. Mol Cells. 2014;37(9):637‐643. doi:10.14348/molcells.2014.0150
Savransky V, Nanayakkara A, Li J, et al. Chronic intermittent hypoxia induces atherosclerosis. Am J Respir Crit Care Med. 2007;175(12):1290‐1297. doi:10.1164/rccm.200612‐1771OC
Pak O, Aldashev A, Welsh D, Peacock A. The effects of hypoxia on the cells of the pulmonary vasculature. Eur Respir J. 2007;30(2):364‐372. doi:10.1183/09031936.00128706
Behrendt T, Bielitzki R, Behrens M, Herold F, Schega L. Effects of intermittent hypoxia‐hyperoxia on performance‐ and health‐related outcomes in humans: a systematic review. Sports Med Open. 2022;8(1):70. doi:10.1186/s40798‐022‐00450‐x
Sharma S, Hashmi MF. Partial Pressure of Oxygen. StatPearls Publishing LLC; 2023.
Carreau A, El Hafny‐Rahbi B, Matejuk A, Grillon C, Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J Cell Mol Med. 2011;15(6):1239‐1253. doi:10.1111/j.1582‐4934.2011.01258.x
Ahmad M, Wolberg A, Kahwaji CI. Biochemistry, Electron Transport Chain. StatPearls Publishing LLC; 2023.
Sarkar M, Niranjan N, Banyal PK. Mechanisms of hypoxemia. Lung India. 2017;34(1):47‐60. doi:10.4103/0970‐2113.197116
LeBlanc A, Matsumoto T, Jones J, et al. Bisphosphonates as a supplement to exercise to protect bone during long‐duration spaceflight. Osteoporos Int. 2013;24(7):2105‐2114. doi:10.1007/s00198‐012‐2243‐z
Thomasius F, Pesta D, Rittweger J. Adjuvant pharmacological strategies for the musculoskeletal system during long‐term space missions. Br J Clin Pharmacol. 2023;1‐13. doi:10.1111/bcp.15877
Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3‐44. doi:10.1007/s00198‐018‐4704‐5
Ramsdell CD, Mullen TJ, Sundby GH, et al. Midodrine prevents orthostatic intolerance associated with simulated spaceflight. J Appl Physiol (1985). 2001;90(6):2245‐2248. doi:10.1152/jappl.2001.90.6.2245
Platts SH, Ziegler MG, Waters WW, Meck JV. Hemodynamic effects of midodrine after spaceflight in astronauts without orthostatic hypotension. Aviat Space Environ Med. 2006;77(4):429‐433.
Brignole M, Moya A, de Lange FJ, et al. 2018 ESC guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39(21):1883‐1948. doi:10.1093/eurheartj/ehy037
Marshall‐Goebel K, Laurie SS, Alferova IV, et al. Assessment of jugular venous blood flow stasis and thrombosis during spaceflight. JAMA Netw Open. 2019;2(11):e1915011. doi:10.1001/jamanetworkopen.2019.15011
Auñón‐Chancellor SM, Pattarini JM, Moll S, Sargsyan A. Venous thrombosis during spaceflight. N Engl J Med. 2020;382(1):89‐90. doi:10.1056/NEJMc1905875
Thienel M, Müller‐Reif JB, Zhang Z, et al. Immobility‐associated thromboprotection is conserved across mammalian species from bear to human. Science. 2023;380(6641):178‐187. doi:10.1126/science.abo5044
McElroy GS, Chandel NS. Mitochondria control acute and chronic responses to hypoxia. Exp Cell Res. 2017;356(2):217‐222. doi:10.1016/j.yexcr.2017.03.034
Ward JP. Oxygen sensors in context. Biochim Biophys Acta. 2008;1777(1):1‐14. doi:10.1016/j.bbabio.2007.10.010
Moreno‐Domínguez A, Colinas O, Smani T, Ureña J, López‐Barneo J. Acute oxygen sensing by vascular smooth muscle cells. Front Physiol. 2023;14:1142354. doi:10.3389/fphys.2023.1142354
Chen P‐S, Chiu W‐T, Hsu P‐L, et al. Pathophysiological implications of hypoxia in human diseases. J Biomed Sci. 2020;27(1):63. doi:10.1186/s12929‐020‐00658‐7
Berchner‐Pfannschmidt U, Tug S, Kirsch M, Fandrey J. Oxygen‐sensing under the influence of nitric oxide. Cell Signal. 2010;22(3):349‐356. doi:10.1016/j.cellsig.2009.10.004
Khatri J, Mills CE, Maskell P, Odongerel C, Webb AJ. It is rocket science—why dietary nitrate is hard to ‘beet’! Part I: twists and turns in the realization of the nitrate‐nitrite‐NO pathway. Br J Clin Pharmacol. 2017;83(1):129‐139. doi:10.1111/bcp.12913
Mills CE, Khatri J, Maskell P, Odongerel C, Webb AJ. It is rocket science—why dietary nitrate is hard to ‘beet’! Part II: further mechanisms and therapeutic potential of the nitrate‐nitrite‐NO pathway. Br J Clin Pharmacol. 2017;83(1):140‐151. doi:10.1111/bcp.12918
Willmott T, Ormesher L, McBain AJ, et al. Altered oral nitrate reduction and bacterial profiles in hypertensive women predict blood pressure lowering following acute dietary nitrate supplementation. Hypertension. 2023;80(11):2397‐2406. doi:10.1161/HYPERTENSIONAHA.123.21263
Merelli A, Rodríguez JCG, Folch J, Regueiro MR, Camins A, Lazarowski A. Understanding the role of hypoxia inducible factor during neurodegeneration for new therapeutics opportunities. Curr Neuropharmacol. 2018;16(10):1484‐1498. doi:10.2174/1570159X16666180110130253
Zheng L, Tian J, Liu D, et al. Efficacy and safety of roxadustat for anaemia in dialysis‐dependent and non‐dialysis‐dependent chronic kidney disease patients: a systematic review and meta‐analysis. Br J Clin Pharmacol. 2022;88(3):919‐932. doi:10.1111/bcp.15055
Böttcher M, Lentini S, Arens ER, et al. First‐in‐man‐proof of concept study with molidustat: a novel selective oral HIF‐prolyl hydroxylase inhibitor for the treatment of renal anaemia. Br J Clin Pharmacol. 2018;84(7):1557‐1565. doi:10.1111/bcp.13584
Ratcliffe PJ, O'Rourke JF, Maxwell PH, Pugh CW. Oxygen sensing, hypoxia‐inducible factor‐1 and the regulation of mammalian gene expression. J Exp Biol. 1998;201(Pt 8):1153‐1162. doi:10.1242/jeb.201.8.1153
Kelly B, O'Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 2015;25(7):771‐784. doi:10.1038/cr.2015.68
Schäfer ST, Frede S, Winning S, et al. Hypoxia‐inducible factor and target gene expression are decreased in patients with sepsis: prospective observational clinical and cellular studies. Anesthesiology. 2013;118(6):1426‐1436. doi:10.1097/ALN.0b013e31828baa67
Hartmann H, Eltzschig HK, Wurz H, et al. Hypoxia‐independent activation of HIF‐1 by enterobacteriaceae and their siderophores. Gastroenterology. 2008;134(3):756‐767. doi:10.1053/j.gastro.2007.12.008
Bishop T, Ratcliffe PJ. HIF hydroxylase pathways in cardiovascular physiology and medicine. Circ Res. 2015;117(1):65‐79. doi:10.1161/CIRCRESAHA.117.305109
Koh MY, Powis G. Passing the baton: the HIF switch. Trends Biochem Sci. 2012;37(9):364‐372. doi:10.1016/j.tibs.2012.06.004
Ghosh MC, Zhang DL, Ollivierre WH, et al. Therapeutic inhibition of HIF‐2α reverses polycythemia and pulmonary hypertension in murine models of human diseases. Blood. 2021;137(18):2509‐2519. doi:10.1182/blood.2020009138
Wicks EE, Semenza GL. Hypoxia‐inducible factors: cancer progression and clinical translation. J Clin Invest. 2022;132(11):e159839. doi:10.1172/JCI159839
Azad P, Stobdan T, Zhou D, et al. High‐altitude adaptation in humans: from genomics to integrative physiology. J Mol Med. 2017;95(12):1269‐1282. doi:10.1007/s00109‐017‐1584‐7
Simonson TS. Altitude Adaptation: A Glimpse Through Various Lenses. High Alt Med Biol. 2015;16(2):125‐137. doi:10.1089/ham.2015.0033
Dagassan PH, Breu V, Clozel M, et al. Up‐regulation of endothelin‐B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol. 1996;27(1):147‐153. doi:10.1097/00005344‐199601000‐00023
Dimitrijevic I, Edvinsson ML, Chen Q, Malmsjö M, Kimblad PO, Edvinsson L. Increased expression of vascular endothelin type B and angiotensin type 1 receptors in patients with ischemic heart disease. BMC Cardiovasc Disord. 2009;9(1):40. doi:10.1186/1471‐2261‐9‐40
Zhou F, Wang F, Li F, et al. Association of hsp70‐2 and hsp‐hom gene polymorphisms with risk of acute high‐altitude illness in a Chinese population. Cell Stress Chaperones. 2005;10(4):349‐356. doi:10.1379/CSC‐156.1
Dzhalilova D, Makarova O. Differences in tolerance to hypoxia: physiological, biochemical, and molecular‐biological characteristics. Biomedicine. 2020;8(10):428. doi:10.3390/biomedicines8100428
West JB. High Life: A History of High‐altitude Physiology and Medicine. 8th ed. Springer; 1998. doi:10.1007/978‐1‐4614‐7573‐6
Swenson ER, Bärtsch P. High Altitude: Human Adaption to Hypoxia. 1st ed. Springer Science+Business Media New York; 2014. doi:10.1007/978‐1‐4614‐8772‐2
Burtscher M, Millet GP, Burtscher J. Hypoxia Conditioning for High‐Altitude Pre‐acclimatization. J Sci Spor Exercise. 2022;4(4):331‐345. doi:10.1007/s42978‐021‐00150‐0
Mallet RT, Burtscher J, Pialoux V, et al. Molecular Mechanisms of High‐Altitude Acclimatization. Int J Mol Sci. 2023;24(2):1698. doi:10.3390/ijms24021698
West JB. Human responses to extreme altitudes. Integr Comp Biol. 2006;46(1):25‐34. doi:10.1093/icb/icj005
Donnelly C, Schmitt S, Cecatto C, et al. The ABC of hypoxia–what is the norm. Bioenergetic Commun. 2022;2022:12.
Houston CS. Operation Everest one and two. Studies of acclimatization to simulated high altitude. Respiration. 1997;64(6):398‐406. doi:10.1159/000196715
Richalet JP. Operation Everest III: COMEX '97. High Alt Med Biol. 2010;11(2):121‐132. doi:10.1089/ham.2009.1099
Hoffmann F, Limper U, Zaha VG, et al. Evolution of pulmonary hypertension during severe sustained hypoxia. Circulation. 2020;141(18):1504‐1506. doi:10.1161/CIRCULATIONAHA.119.045192
Limper U, Hoffmann F, Zaha VG, et al. Disconnect between hypoxaemia and dyspnoea in severe sustained hypoxia. Eur J Anaesthesiol. 2021;38(7):798‐800. doi:10.1097/EJA.0000000000001478
Sönksen SE, Kühn S, Basner M, et al. Brain structure and neurocognitive function in two professional mountaineers during 35 days of severe normobaric hypoxia. Eur J Neurol. 2022;29(10):3112‐3116. doi:10.1111/ene.15470
Hönemann J‐N, Gerlach D, Hoffmann F, et al. Hypoxia and cardiac function in patients with prior myocardial infarction. Circ Res. 2023;132(9):1165‐1167. doi:10.1161/CIRCRESAHA.122.322334
Forrer A, Gaisl T, Sevik A, et al. Partial pressure of arterial oxygen in healthy adults at high altitudes: a systematic review and meta‐analysis. JAMA Netw Open. 2023;6(6):e2318036‐e. doi:10.1001/jamanetworkopen.2023.18036
Coppel J, Hennis P, Gilbert‐Kawai E, Grocott MP. The physiological effects of hypobaric hypoxia versus normobaric hypoxia: a systematic review of crossover trials. Extrem Physiol Med. 2015;4(1):2. doi:10.1186/s13728‐014‐0021‐6
Rosales AM, Shute RJ, Hailes WS, Collins CW, Ruby BC, Slivka DR. Independent effects of acute normobaric hypoxia and hypobaric hypoxia on human physiology. Sci Rep. 2022;12(1):1‐10.
Loredo JS, Clausen JL, Nelesen RA, Ancoli‐Israel S, Ziegler MG, Dimsdale JE. Obstructive sleep apnea and hypertension: are peripheral chemoreceptors involved? Med Hypotheses. 2001;56(1):17‐19. doi:10.1054/mehy.2000.1086
Heusser K, Thöne A, Lipp A, et al. Efficacy of electrical baroreflex activation is independent of peripheral chemoreceptor modulation. Hypertension. 2020;75(1):257‐264. doi:10.1161/HYPERTENSIONAHA.119.13925
Gerlach DA, Manuel J, Hoff A, et al. Medullary and hypothalamic functional magnetic imaging during acute hypoxia in tracing human peripheral chemoreflex responses. Hypertension. 2021;77(4):1372‐1382. doi:10.1161/HYPERTENSIONAHA.120.16385
Halliwill JR, Morgan BJ, Charkoudian N. Peripheral chemoreflex and baroreflex interactions in cardiovascular regulation in humans. J Physiol. 2003;552(Pt 1):295‐302. doi:10.1113/jphysiol.2003.050708
Luo Z, Tian M, Yang G, et al. Hypoxia signaling in human health and diseases: implications and prospects for therapeutics. Signal Transduct Target Ther. 2022;7(1):218. doi:10.1038/s41392‐022‐01080‐1
Naeije R, Richter MJ, Rubin LJ. The physiological basis of pulmonary arterial hypertension. Eur Respir J. 2022;59(6):2102334. doi:10.1183/13993003.02334‐2021
Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary arterial hypertension: the clinical syndrome. Circ Res. 2014;115(1):115‐130. doi:10.1161/CIRCRESAHA.115.301146
Garrod R, Paul EA, Wedzicha JA. Supplemental oxygen during pulmonary rehabilitation in patients with COPD with exercise hypoxaemia. Thorax. 2000;55(7):539‐543. doi:10.1136/thorax.55.7.539
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618‐3731. doi:10.1093/eurheartj/ehac237
Agustí A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc Am Thorac Soc. 2007;4(7):522‐525. doi:10.1513/pats.200701‐004FM
Agustí A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Am J Respir Crit Care Med. 2023;207(7):819‐837. doi:10.1164/rccm.202301‐0106PP
Barberà JA, Roca J, Ferrer A, et al. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 1997;10(6):1285‐1291. doi:10.1183/09031936.97.10061285
Mikami Y, Grubb BR, Rogers TD, et al. Chronic airway epithelial hypoxia exacerbates injury in muco‐obstructive lung disease through mucus hyperconcentration. Sci Transl Med. 2023;15(699):eabo7728. doi:10.1126/scitranslmed.abo7728
Baloglu E, Nonnenmacher G, Seleninova A, et al. The role of hypoxia‐induced modulation of alveolar epithelial Na(+)‐transport in hypoxemia at high altitude. Pulm Circ. 2020;10(1 Suppl):50‐58. doi:10.1177/2045894020936662
McNicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnea: overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am J Respir Crit Care Med. 2009;180(8):692‐700. doi:10.1164/rccm.200903‐0347PP
Tuleta I, Farrag T, Busse L, et al. High prevalence of COPD in atherosclerosis patients. Int J Chron Obstruct Pulmon Dis. 2017;12:3047‐3053. doi:10.2147/COPD.S141988
Mirabile VS, Shebl E, Sankari A, Burns B. Respiratory Failure. StatPearls Publishing LLC; 2023.
Cukic V. The changes of arterial blood gases in COPD during four‐year period. Med Arch. 2014;68(1):14‐18. doi:10.5455/medarh.2014.68.14‐18
Wolk R, Kara T, Somers VK. Sleep‐disordered breathing and cardiovascular disease. Circulation. 2003;108(1):9‐12. doi:10.1161/01.CIR.0000072346.56728.E4
Gell LK, Vena D, Alex RM, et al. Neural ventilatory drive decline as a predominant mechanism of obstructive sleep apnoea events. Thorax. 2022;77(7):707‐716. doi:10.1136/thoraxjnl‐2021‐217756
Peracaula M, Torres D, Poyatos P, et al. Endothelial dysfunction and cardiovascular risk in obstructive sleep apnea: a review article. Life (Basel). 2022;12(4):537. doi:10.3390/life12040537
Dempsey JA, Veasey SC, Morgan BJ, O'Donnell CP. Pathophysiology of sleep apnea. Physiol Rev. 2010;90(1):47‐112. doi:10.1152/physrev.00043.2008
Rojas‐Córdova S, Torres‐Fraga MG, Rodríguez‐Reyes YG, Guerrero‐Zúñiga S, Vázquez‐García JC, Carrillo‐Alduenda JL. Altitude and breathing during sleep in healthy persons and sleep disordered patients: a systematic review. Sleep Sci. 2023;16(1):117‐126. doi:10.1055/s‐0043‐1767745
Lavie L, Lavie P. Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. Eur Respir J. 2009;33(6):1467‐1484. doi:10.1183/09031936.00086608
Atkeson A, Jelic S. Mechanisms of endothelial dysfunction in obstructive sleep apnea. Vasc Health Risk Manag. 2008;4(6):1327‐1335. doi:10.2147/VHRM.S4078
Atkeson A, Yeh SY, Malhotra A, Jelic S. Endothelial function in obstructive sleep apnea. Prog Cardiovasc Dis. 2009;51(5):351‐362. doi:10.1016/j.pcad.2008.08.002
Mateika JH. A reminder that experimentally induced intermittent hypoxia is an incomplete model of obstructive sleep apnea and its outcome measures. J Appl Physiol (1985). 2019;127(6):1620‐1621. doi:10.1152/japplphysiol.00549.2019
Beaudin AE, Pun M, Yang C, et al. Cyclooxygenases 1 and 2 differentially regulate blood pressure and cerebrovascular responses to acute and chronic intermittent hypoxia: implications for sleep apnea. J Am Heart Assoc. 2014;3(3):e000875. doi:10.1161/JAHA.114.000875
Navarrete‐Opazo A, Mitchell GS. Therapeutic potential of intermittent hypoxia: a matter of dose. Am J Physiol Regul Integr Comp Physiol. 2014;307(10):R1181. doi:10.1152/ajpregu.00208.2014
Younes M, Ostrowski M, Atkar R, Laprairie J, Siemens A, Hanly P. Mechanisms of breathing instability in patients with obstructive sleep apnea. J Appl Physiol (1985). 2007;103(6):1929‐1941. doi:10.1152/japplphysiol.00561.2007
Cutrer FM, Charles A. The neurogenic basis of migraine. Headache. 2008;48(9):1411‐1414. doi:10.1111/j.1526‐4610.2008.01277.x
Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci. 2003;4(5):386‐398. doi:10.1038/nrn1102
Broessner G, Rohregger J, Wille M, Lackner P, Ndayisaba JP, Burtscher M. Hypoxia triggers high‐altitude headache with migraine features: a prospective trial. Cephalalgia. 2016;36(8):765‐771. doi:10.1177/0333102415610876
Wang M, Lan D, Dandu C, Ding Y, Ji X, Meng R. Normobaric oxygen may attenuate the headache in patients with patent foramen povale and migraine. BMC Neurol. 2023;23(1):44. doi:10.1186/s12883‐023‐03059‐z
Frank F, Faulhaber M, Messlinger K, et al. Migraine and aura triggered by normobaric hypoxia. Cephalalgia. 2020;40(14):1561‐1573. doi:10.1177/0333102420949202
Arngrim N, Schytz HW, Britze J, et al. Migraine induced by hypoxia: an MRI spectroscopy and angiography study. Brain. 2016;139(Pt 3):723‐737. doi:10.1093/brain/awv359
Schoonman GG, Sándor PS, Agosti RM, et al. Normobaric hypoxia and nitroglycerin as trigger factors for migraine. Cephalalgia. 2006;26(7):816‐819. doi:10.1111/j.1468‐2982.2006.01112.x
Sureda‐Gibert P, Romero‐Reyes M, Akerman S. Nitroglycerin as a model of migraine: clinical and preclinical review. Neurobiol Pain. 2022;12:100105. doi:10.1016/j.ynpai.2022.100105
Tfelt‐Hansen PC, Koehler PJ. One hundred years of migraine research: major clinical and scientific observations from 1910 to 2010. Headache. 2011;51(5):752‐778. doi:10.1111/j.1526‐4610.2011.01892.x
Sonn J, Mayevsky A. Responses to cortical spreading depression under oxygen deficiency. Open Neurol J. 2012;6(1):6‐17. doi:10.2174/1874205X01206010006
Aggarwal M, Puri V, Puri S. Serotonin and CGRP in migraine. Ann Neurosci. 2012;19(2):88‐94. doi:10.5214/ans.0972.7531.12190210
Andress‐Rothrock D, King W, Rothrock J. An analysis of migraine triggers in a clinic‐based population. Headache. 2010;50(8):1366‐1370. doi:10.1111/j.1526‐4610.2010.01753.x
Genizi J, Halevy A, Schertz M, et al. Sensory processing patterns affect headache severity among adolescents with migraine. J Headache Pain. 2020;21(1):48. doi:10.1186/s10194‐020‐01119‐0
Donnelly S. Why is erythropoietin made in the kidney? The kidney functions as a critmeter. Am J Kidney Dis. 2001;38(2):415‐425. doi:10.1053/ajkd.2001.26111
Mannix ET, Dowdeswell I, Carlone S, Palange P, Aronoff GR, Farber MO. The effect of oxygen on sodium excretion in hypoxemic patients with chronic obstructive lung disease. Chest. 1990;97(4):840‐844. doi:10.1378/chest.97.4.840
Kilburn KH, Dowell AR. Renal function in respiratory failure. Effects of hypoxia, hyperoxia, and hypercapnia. Arch Intern Med. 1971;127(4):754‐762. doi:10.1001/archinte.1971.00310160232020
Perticone M, Maio R, Scarpino PE, et al. Continuous positive airway pressure improves renal function in obese patients with obstructive sleep apnea syndrome. Front Med (Lausanne). 2021;8:642086. doi:10.3389/fmed.2021.642086
Bärtsch P, Swenson ER, Paul A, Jülg B, Hohenhaus E. Hypoxic ventilatory response, ventilation, gas exchange, and fluid balance in acute mountain sickness. High Alt Med Biol. 2002;3(4):361‐376. doi:10.1089/15270290260512846
Bullen A, Liu ZZ, Hepokoski M, Li Y, Singh P. Renal oxygenation and hemodynamics in kidney injury. Nephron. 2017;137(4):260‐263. doi:10.1159/000477830
Li H, Satriano J, Thomas JL, et al. Interactions between HIF‐1α and AMPK in the regulation of cellular hypoxia adaptation in chronic kidney disease. Am J Physiol Renal Physiol. 2015;309(5):F414‐F428. doi:10.1152/ajprenal.00463.2014
Mohaupt M, Kramer HJ. Acute ischemic renal failure: review of experimental studies on pathophysiology and potential protective interventions. Ren Fail. 1989;11(4):177‐185. doi:10.3109/08860228909054929
Abstracts of presentations at the Association of Clinical Scientists 143rd meeting Louisville, KY May 11‐14, 2022. Ann Clin Lab Sci. 2022;52(3):511‐525.
Legrand M, Mik EG, Johannes T, Payen D, Ince C. Renal hypoxia and dysoxia after reperfusion of the ischemic kidney. Mol Med. 2008;14(7–8):502‐516. doi:10.2119/2008‐00006.Legrand
Sedlacek M, Harlan NP, Buckey JC. Renal effects of hyperbaric oxygen therapy in patients with diabetes mellitus: a retrospective study. Int J Nephrol. 2021;2021:9992352. doi:10.1155/2021/9992352
Watt M, Peacock A, Newell J, McDonagh T, Grant S. The effect of amlodipine on respiratory and pulmonary vascular responses to hypoxia in mountaineers. Eur Respir J. 2000;15(3):459. doi:10.1034/j.1399‐3003.2000.15.06.x
Pham I, Wuerzner G, Richalet J‐P, Peyrard S, Azizi M. Endothelin receptors blockade blunts hypoxia‐induced increase in PAP in humans. Eur J Clin Invest. 2010;40(3):195‐202. doi:10.1111/j.1365‐2362.2010.02254.x
Faoro V, Boldingh S, Moreels M, et al. Bosentan Decreases Pulmonary Vascular Resistance and Improves Exercise Capacity in Acute Hypoxia. Chest. 2009;135(5):1215‐1222. doi:10.1378/chest.08‐2222
Ghofrani HA, Reichenberger F, Kohstall MG, et al. Sildenafil Increased Exercise Capacity during Hypoxia at Low Altitudes and at Mount Everest Base Camp. Ann Intern Med. 2004;141(3):169. doi:10.7326/0003‐4819‐141‐3‐200408030‐00005
Ricart A, Maristany J, Fort N, Leal C, Pagés T, Viscor G. Effects of Sildenafil on the Human Response to Acute Hypoxia and Exercise. High Alt Med Biol. 2005;6(1):43‐49. doi:10.1089/ham.2005.6.43
Damy T, Hobkirk J, Walters M, et al. Development of a Human Model for the Study of Effects of Hypoxia, Exercise, and Sildenafil on Cardiac and Vascular Function in Chronic Heart Failure. J Cardiovasc Pharmacol. 2015;66(3):229‐238. doi:10.1097/fjc.0000000000000262
Burghuber OC. Nifedipine Attenuates Acute Hypoxic Pulmonary Vasoconstriction in Patients with Chronic Obstructive Pulmonary Disease. Respiration. 1987;52(2):86‐93. doi:10.1159/000195309
Straus C, Teulier M, Morel S, et al. Baclofen destabilises breathing during sleep in healthy humans: A randomised, controlled, double‐blind crossover trial. Br J Clin Pharmacol. 2020;87(4):1814‐1823. Portico. https://doi.org/10.1111/bcp.14569
Foster GE, Hanly PJ, Ahmed SB, Beaudin AE, Pialoux V, Poulin MJ. Intermittent Hypoxia Increases Arterial Blood Pressure in Humans Through a Renin‐Angiotensin System‐Dependent Mechanism. Hypertension. 2010;56(3):369‐377. https://doi.org/10.1161/hypertensionaha.110.152108
Pavelescu A, Naeije R. Effects of epoprostenol and sildenafil on right ventricular function in hypoxic volunteers: a tissue Doppler imaging study. Eur J Appl Physiol. 2011;112(4):1285‐1294. doi:10.1007/s00421‐011‐2085‐y
Didier KD, Muer JD, Wannebo BM, et al. Effect of Cyclooxygenase Inhibitor on Hypoxia Stimulated Cerebral Blood Flow Using Arterial Spin Labeling Magnetic Resonance. FASEB J. 2022;36(S1). doi:10.1096/fasebj.2022.36.s1.0r879
Kruizinga MD, Stuurman FE, Exadaktylos V, et al. Development of novel, value‐based, digital endpoints for clinical trials: a structured approach toward fit‐for‐purpose validation. Pharmacol Rev. 2020;72(4):899‐909. doi:10.1124/pr.120.000028
Clément G, Rittweger J, Nitsche A, et al. Assessing the effects of artificial gravity in an analog of long‐duration spaceflight: the protocol and implementation of the AGBRESA bed rest study. Front Physiol. 2022;13:976926. doi:10.3389/fphys.2022.976926